nodes	percent_of_prediction	percent_of_DWPC	metapath
Rimonabant—CYP1A2—Sorafenib—thyroid cancer	0.134	0.203	CbGbCtD
Rimonabant—CYP2C9—Sorafenib—thyroid cancer	0.12	0.183	CbGbCtD
Rimonabant—CYP3A4—Vandetanib—thyroid cancer	0.116	0.176	CbGbCtD
Rimonabant—CYP2D6—Sorafenib—thyroid cancer	0.11	0.167	CbGbCtD
Rimonabant—CYP3A4—Sorafenib—thyroid cancer	0.0701	0.106	CbGbCtD
Rimonabant—CYP2D6—Doxorubicin—thyroid cancer	0.0668	0.101	CbGbCtD
Rimonabant—CYP3A4—Doxorubicin—thyroid cancer	0.0425	0.0644	CbGbCtD
Rimonabant—Mood alteration NOS—Sorafenib—thyroid cancer	0.0321	0.0962	CcSEcCtD
Rimonabant—Gastroenteritis—Vandetanib—thyroid cancer	0.00782	0.0234	CcSEcCtD
Rimonabant—Hypoglycaemia—Vandetanib—thyroid cancer	0.0071	0.0213	CcSEcCtD
Rimonabant—Lethargy—Vandetanib—thyroid cancer	0.00707	0.0212	CcSEcCtD
Rimonabant—Influenza—Vandetanib—thyroid cancer	0.00599	0.018	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00557	0.0167	CcSEcCtD
Rimonabant—Infestation NOS—Vandetanib—thyroid cancer	0.00534	0.016	CcSEcCtD
Rimonabant—Infestation—Vandetanib—thyroid cancer	0.00534	0.016	CcSEcCtD
Rimonabant—Depression—Vandetanib—thyroid cancer	0.00532	0.016	CcSEcCtD
Rimonabant—Sinusitis—Vandetanib—thyroid cancer	0.00501	0.015	CcSEcCtD
Rimonabant—Mood swings—Sorafenib—thyroid cancer	0.00443	0.0133	CcSEcCtD
Rimonabant—Angiopathy—Vandetanib—thyroid cancer	0.00435	0.013	CcSEcCtD
Rimonabant—Mediastinal disorder—Vandetanib—thyroid cancer	0.00432	0.013	CcSEcCtD
Rimonabant—Mental disorder—Vandetanib—thyroid cancer	0.0042	0.0126	CcSEcCtD
Rimonabant—Malnutrition—Vandetanib—thyroid cancer	0.00417	0.0125	CcSEcCtD
Rimonabant—Muscle spasms—Vandetanib—thyroid cancer	0.00401	0.012	CcSEcCtD
Rimonabant—Tremor—Vandetanib—thyroid cancer	0.00391	0.0117	CcSEcCtD
Rimonabant—Abdominal discomfort—Sorafenib—thyroid cancer	0.00387	0.0116	CcSEcCtD
Rimonabant—Convulsion—Vandetanib—thyroid cancer	0.00362	0.0108	CcSEcCtD
Rimonabant—Infestation NOS—Sorafenib—thyroid cancer	0.0036	0.0108	CcSEcCtD
Rimonabant—Infestation—Sorafenib—thyroid cancer	0.0036	0.0108	CcSEcCtD
Rimonabant—Anxiety—Vandetanib—thyroid cancer	0.00354	0.0106	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00353	0.0106	CcSEcCtD
Rimonabant—Dry mouth—Vandetanib—thyroid cancer	0.00347	0.0104	CcSEcCtD
Rimonabant—Infection—Vandetanib—thyroid cancer	0.00338	0.0101	CcSEcCtD
Rimonabant—Nervous system disorder—Vandetanib—thyroid cancer	0.00334	0.01	CcSEcCtD
Rimonabant—Skin disorder—Vandetanib—thyroid cancer	0.00331	0.00992	CcSEcCtD
Rimonabant—Connective tissue disorder—Sorafenib—thyroid cancer	0.00318	0.00953	CcSEcCtD
Rimonabant—Insomnia—Vandetanib—thyroid cancer	0.00308	0.00924	CcSEcCtD
Rimonabant—Paraesthesia—Vandetanib—thyroid cancer	0.00306	0.00917	CcSEcCtD
Rimonabant—Decreased appetite—Vandetanib—thyroid cancer	0.00296	0.00888	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00294	0.00882	CcSEcCtD
Rimonabant—Fatigue—Vandetanib—thyroid cancer	0.00294	0.0088	CcSEcCtD
Rimonabant—Angiopathy—Sorafenib—thyroid cancer	0.00293	0.0088	CcSEcCtD
Rimonabant—Mediastinal disorder—Sorafenib—thyroid cancer	0.00291	0.00874	CcSEcCtD
Rimonabant—Mental disorder—Sorafenib—thyroid cancer	0.00283	0.00849	CcSEcCtD
Rimonabant—Malnutrition—Sorafenib—thyroid cancer	0.00282	0.00844	CcSEcCtD
Rimonabant—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00279	0.00835	CcSEcCtD
Rimonabant—Muscle spasms—Sorafenib—thyroid cancer	0.00271	0.00812	CcSEcCtD
Rimonabant—Abdominal pain—Vandetanib—thyroid cancer	0.00269	0.00807	CcSEcCtD
Rimonabant—Asthenia—Vandetanib—thyroid cancer	0.00244	0.00733	CcSEcCtD
Rimonabant—Pruritus—Vandetanib—thyroid cancer	0.00241	0.00723	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00238	0.00714	CcSEcCtD
Rimonabant—Hiccups—Epirubicin—thyroid cancer	0.00238	0.00714	CcSEcCtD
Rimonabant—Dry mouth—Sorafenib—thyroid cancer	0.00234	0.00703	CcSEcCtD
Rimonabant—Diarrhoea—Vandetanib—thyroid cancer	0.00233	0.00699	CcSEcCtD
Rimonabant—Infection—Sorafenib—thyroid cancer	0.00228	0.00684	CcSEcCtD
Rimonabant—Nervous system disorder—Sorafenib—thyroid cancer	0.00225	0.00676	CcSEcCtD
Rimonabant—Dizziness—Vandetanib—thyroid cancer	0.00225	0.00675	CcSEcCtD
Rimonabant—Skin disorder—Sorafenib—thyroid cancer	0.00223	0.00669	CcSEcCtD
Rimonabant—Hiccups—Doxorubicin—thyroid cancer	0.0022	0.0066	CcSEcCtD
Rimonabant—Anorexia—Sorafenib—thyroid cancer	0.00219	0.00657	CcSEcCtD
Rimonabant—Vomiting—Vandetanib—thyroid cancer	0.00217	0.00649	CcSEcCtD
Rimonabant—Rash—Vandetanib—thyroid cancer	0.00215	0.00644	CcSEcCtD
Rimonabant—Dermatitis—Vandetanib—thyroid cancer	0.00215	0.00643	CcSEcCtD
Rimonabant—Headache—Vandetanib—thyroid cancer	0.00213	0.0064	CcSEcCtD
Rimonabant—Nausea—Vandetanib—thyroid cancer	0.00202	0.00607	CcSEcCtD
Rimonabant—Decreased appetite—Sorafenib—thyroid cancer	0.002	0.00599	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00198	0.00595	CcSEcCtD
Rimonabant—Fatigue—Sorafenib—thyroid cancer	0.00198	0.00594	CcSEcCtD
Rimonabant—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00188	0.00563	CcSEcCtD
Rimonabant—Hot flush—Epirubicin—thyroid cancer	0.00185	0.00554	CcSEcCtD
Rimonabant—Menopausal symptoms—Epirubicin—thyroid cancer	0.00183	0.00549	CcSEcCtD
Rimonabant—Abdominal pain—Sorafenib—thyroid cancer	0.00182	0.00545	CcSEcCtD
Rimonabant—Hypoglycaemia—Epirubicin—thyroid cancer	0.00177	0.00531	CcSEcCtD
Rimonabant—Lethargy—Epirubicin—thyroid cancer	0.00176	0.00529	CcSEcCtD
Rimonabant—Hot flush—Doxorubicin—thyroid cancer	0.00171	0.00512	CcSEcCtD
Rimonabant—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00169	0.00508	CcSEcCtD
Rimonabant—Asthenia—Sorafenib—thyroid cancer	0.00165	0.00494	CcSEcCtD
Rimonabant—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00164	0.00491	CcSEcCtD
Rimonabant—Mood swings—Epirubicin—thyroid cancer	0.00164	0.00491	CcSEcCtD
Rimonabant—Lethargy—Doxorubicin—thyroid cancer	0.00163	0.00489	CcSEcCtD
Rimonabant—Pruritus—Sorafenib—thyroid cancer	0.00163	0.00487	CcSEcCtD
Rimonabant—Diarrhoea—Sorafenib—thyroid cancer	0.00157	0.00471	CcSEcCtD
Rimonabant—Dizziness—Sorafenib—thyroid cancer	0.00152	0.00456	CcSEcCtD
Rimonabant—Mood swings—Doxorubicin—thyroid cancer	0.00151	0.00454	CcSEcCtD
Rimonabant—Influenza—Epirubicin—thyroid cancer	0.00149	0.00448	CcSEcCtD
Rimonabant—Vomiting—Sorafenib—thyroid cancer	0.00146	0.00438	CcSEcCtD
Rimonabant—Rash—Sorafenib—thyroid cancer	0.00145	0.00434	CcSEcCtD
Rimonabant—Dermatitis—Sorafenib—thyroid cancer	0.00145	0.00434	CcSEcCtD
Rimonabant—Headache—Sorafenib—thyroid cancer	0.00144	0.00432	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00139	0.00416	CcSEcCtD
Rimonabant—Influenza—Doxorubicin—thyroid cancer	0.00138	0.00414	CcSEcCtD
Rimonabant—Nausea—Sorafenib—thyroid cancer	0.00136	0.00409	CcSEcCtD
Rimonabant—Infestation NOS—Epirubicin—thyroid cancer	0.00133	0.00399	CcSEcCtD
Rimonabant—Infestation—Epirubicin—thyroid cancer	0.00133	0.00399	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00128	0.00385	CcSEcCtD
Rimonabant—Sinusitis—Epirubicin—thyroid cancer	0.00125	0.00375	CcSEcCtD
Rimonabant—Infestation—Doxorubicin—thyroid cancer	0.00123	0.00369	CcSEcCtD
Rimonabant—Infestation NOS—Doxorubicin—thyroid cancer	0.00123	0.00369	CcSEcCtD
Rimonabant—Hypoaesthesia—Epirubicin—thyroid cancer	0.00119	0.00357	CcSEcCtD
Rimonabant—Connective tissue disorder—Epirubicin—thyroid cancer	0.00117	0.00352	CcSEcCtD
Rimonabant—Sinusitis—Doxorubicin—thyroid cancer	0.00116	0.00347	CcSEcCtD
Rimonabant—Hypoaesthesia—Doxorubicin—thyroid cancer	0.0011	0.0033	CcSEcCtD
Rimonabant—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00109	0.00326	CcSEcCtD
Rimonabant—Angiopathy—Epirubicin—thyroid cancer	0.00108	0.00325	CcSEcCtD
Rimonabant—Mediastinal disorder—Epirubicin—thyroid cancer	0.00108	0.00323	CcSEcCtD
Rimonabant—Mental disorder—Epirubicin—thyroid cancer	0.00105	0.00314	CcSEcCtD
Rimonabant—Malnutrition—Epirubicin—thyroid cancer	0.00104	0.00312	CcSEcCtD
Rimonabant—Tension—Epirubicin—thyroid cancer	0.00102	0.00306	CcSEcCtD
Rimonabant—Nervousness—Epirubicin—thyroid cancer	0.00101	0.00303	CcSEcCtD
Rimonabant—Angiopathy—Doxorubicin—thyroid cancer	0.001	0.00301	CcSEcCtD
Rimonabant—Muscle spasms—Epirubicin—thyroid cancer	0.001	0.003	CcSEcCtD
Rimonabant—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000997	0.00299	CcSEcCtD
Rimonabant—Mental disorder—Doxorubicin—thyroid cancer	0.000969	0.0029	CcSEcCtD
Rimonabant—Malnutrition—Doxorubicin—thyroid cancer	0.000963	0.00289	CcSEcCtD
Rimonabant—Tension—Doxorubicin—thyroid cancer	0.000945	0.00283	CcSEcCtD
Rimonabant—Nervousness—Doxorubicin—thyroid cancer	0.000935	0.0028	CcSEcCtD
Rimonabant—Muscle spasms—Doxorubicin—thyroid cancer	0.000926	0.00278	CcSEcCtD
Rimonabant—Convulsion—Epirubicin—thyroid cancer	0.000901	0.0027	CcSEcCtD
Rimonabant—Anxiety—Epirubicin—thyroid cancer	0.000883	0.00265	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00088	0.00264	CcSEcCtD
Rimonabant—Dry mouth—Epirubicin—thyroid cancer	0.000866	0.0026	CcSEcCtD
Rimonabant—Infection—Epirubicin—thyroid cancer	0.000844	0.00253	CcSEcCtD
Rimonabant—Convulsion—Doxorubicin—thyroid cancer	0.000834	0.0025	CcSEcCtD
Rimonabant—Nervous system disorder—Epirubicin—thyroid cancer	0.000833	0.0025	CcSEcCtD
Rimonabant—Skin disorder—Epirubicin—thyroid cancer	0.000825	0.00247	CcSEcCtD
Rimonabant—Hyperhidrosis—Epirubicin—thyroid cancer	0.000821	0.00246	CcSEcCtD
Rimonabant—Anxiety—Doxorubicin—thyroid cancer	0.000817	0.00245	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000814	0.00244	CcSEcCtD
Rimonabant—Anorexia—Epirubicin—thyroid cancer	0.000809	0.00243	CcSEcCtD
Rimonabant—Dry mouth—Doxorubicin—thyroid cancer	0.000802	0.0024	CcSEcCtD
Rimonabant—Infection—Doxorubicin—thyroid cancer	0.000781	0.00234	CcSEcCtD
Rimonabant—Nervous system disorder—Doxorubicin—thyroid cancer	0.00077	0.00231	CcSEcCtD
Rimonabant—Insomnia—Epirubicin—thyroid cancer	0.000768	0.0023	CcSEcCtD
Rimonabant—Skin disorder—Doxorubicin—thyroid cancer	0.000763	0.00229	CcSEcCtD
Rimonabant—Paraesthesia—Epirubicin—thyroid cancer	0.000762	0.00229	CcSEcCtD
Rimonabant—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000759	0.00228	CcSEcCtD
Rimonabant—Anorexia—Doxorubicin—thyroid cancer	0.000749	0.00225	CcSEcCtD
Rimonabant—Decreased appetite—Epirubicin—thyroid cancer	0.000738	0.00221	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000733	0.0022	CcSEcCtD
Rimonabant—Fatigue—Epirubicin—thyroid cancer	0.000732	0.00219	CcSEcCtD
Rimonabant—Insomnia—Doxorubicin—thyroid cancer	0.000711	0.00213	CcSEcCtD
Rimonabant—Paraesthesia—Doxorubicin—thyroid cancer	0.000705	0.00212	CcSEcCtD
Rimonabant—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000694	0.00208	CcSEcCtD
Rimonabant—Decreased appetite—Doxorubicin—thyroid cancer	0.000683	0.00205	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000678	0.00203	CcSEcCtD
Rimonabant—Fatigue—Doxorubicin—thyroid cancer	0.000677	0.00203	CcSEcCtD
Rimonabant—Abdominal pain—Epirubicin—thyroid cancer	0.000671	0.00201	CcSEcCtD
Rimonabant—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000642	0.00193	CcSEcCtD
Rimonabant—Abdominal pain—Doxorubicin—thyroid cancer	0.000621	0.00186	CcSEcCtD
Rimonabant—Asthenia—Epirubicin—thyroid cancer	0.000609	0.00183	CcSEcCtD
Rimonabant—Pruritus—Epirubicin—thyroid cancer	0.000601	0.0018	CcSEcCtD
Rimonabant—Diarrhoea—Epirubicin—thyroid cancer	0.000581	0.00174	CcSEcCtD
Rimonabant—Asthenia—Doxorubicin—thyroid cancer	0.000564	0.00169	CcSEcCtD
Rimonabant—Dizziness—Epirubicin—thyroid cancer	0.000561	0.00168	CcSEcCtD
Rimonabant—Pruritus—Doxorubicin—thyroid cancer	0.000556	0.00167	CcSEcCtD
Rimonabant—Vomiting—Epirubicin—thyroid cancer	0.00054	0.00162	CcSEcCtD
Rimonabant—Diarrhoea—Doxorubicin—thyroid cancer	0.000538	0.00161	CcSEcCtD
Rimonabant—Rash—Epirubicin—thyroid cancer	0.000535	0.00161	CcSEcCtD
Rimonabant—Dermatitis—Epirubicin—thyroid cancer	0.000535	0.0016	CcSEcCtD
Rimonabant—Headache—Epirubicin—thyroid cancer	0.000532	0.00159	CcSEcCtD
Rimonabant—Dizziness—Doxorubicin—thyroid cancer	0.00052	0.00156	CcSEcCtD
Rimonabant—Nausea—Epirubicin—thyroid cancer	0.000504	0.00151	CcSEcCtD
Rimonabant—Vomiting—Doxorubicin—thyroid cancer	0.0005	0.0015	CcSEcCtD
Rimonabant—Rash—Doxorubicin—thyroid cancer	0.000495	0.00149	CcSEcCtD
Rimonabant—Dermatitis—Doxorubicin—thyroid cancer	0.000495	0.00148	CcSEcCtD
Rimonabant—Headache—Doxorubicin—thyroid cancer	0.000492	0.00148	CcSEcCtD
Rimonabant—Nausea—Doxorubicin—thyroid cancer	0.000467	0.0014	CcSEcCtD
Rimonabant—CNR2—GPCR ligand binding—CALCB—thyroid cancer	0.000268	0.0404	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—CALCB—thyroid cancer	0.00021	0.0317	CbGpPWpGaD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000163	0.0246	CbGpPWpGaD
Rimonabant—CNR2—G alpha (i) signalling events—SST—thyroid cancer	0.000159	0.024	CbGpPWpGaD
Rimonabant—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000156	0.0235	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—CALCB—thyroid cancer	0.000151	0.0228	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CALCB—thyroid cancer	0.000138	0.0207	CbGpPWpGaD
Rimonabant—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000135	0.0203	CbGpPWpGaD
Rimonabant—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000133	0.0201	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00013	0.0197	CbGpPWpGaD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000128	0.0193	CbGpPWpGaD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000127	0.0191	CbGpPWpGaD
Rimonabant—CNR1—G alpha (i) signalling events—SST—thyroid cancer	0.000125	0.0189	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—TSHR—thyroid cancer	0.000124	0.0187	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—CALCB—thyroid cancer	0.000119	0.0179	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CALCB—thyroid cancer	0.000108	0.0163	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—PTCH1—thyroid cancer	0.000106	0.0159	CbGpPWpGaD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	9.95e-05	0.015	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—TSHR—thyroid cancer	9.74e-05	0.0147	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—SST—thyroid cancer	9.65e-05	0.0146	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—CALCA—thyroid cancer	9.29e-05	0.014	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—PTCH1—thyroid cancer	8.28e-05	0.0125	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CALCB—thyroid cancer	8.13e-05	0.0123	CbGpPWpGaD
Rimonabant—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	8.06e-05	0.0122	CbGpPWpGaD
Rimonabant—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	8.06e-05	0.0122	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TRIM33—thyroid cancer	7.7e-05	0.0116	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—SST—thyroid cancer	7.57e-05	0.0114	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—CALCA—thyroid cancer	7.29e-05	0.011	CbGpPWpGaD
Rimonabant—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	7.17e-05	0.0108	CbGpPWpGaD
Rimonabant—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	7.11e-05	0.0107	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—TSHR—thyroid cancer	7.01e-05	0.0106	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CALCB—thyroid cancer	6.38e-05	0.00962	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—TSHR—thyroid cancer	6.37e-05	0.0096	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PRKAR1A—thyroid cancer	6.27e-05	0.00945	CbGpPWpGaD
Rimonabant—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	6.07e-05	0.00916	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TRIM33—thyroid cancer	6.05e-05	0.00912	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—TSHR—thyroid cancer	5.5e-05	0.0083	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—SST—thyroid cancer	5.45e-05	0.00823	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PTCH1—thyroid cancer	5.42e-05	0.00817	CbGpPWpGaD
Rimonabant—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	5.31e-05	0.00801	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—CALCA—thyroid cancer	5.25e-05	0.00792	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TCF7L1—thyroid cancer	5.14e-05	0.00775	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—TSHR—thyroid cancer	5e-05	0.00754	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—SST—thyroid cancer	4.95e-05	0.00747	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PRKAR1A—thyroid cancer	4.92e-05	0.00741	CbGpPWpGaD
Rimonabant—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	4.92e-05	0.00741	CbGpPWpGaD
Rimonabant—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	4.87e-05	0.00735	CbGpPWpGaD
Rimonabant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	4.85e-05	0.00731	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CALCA—thyroid cancer	4.77e-05	0.00719	CbGpPWpGaD
Rimonabant—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	4.69e-05	0.00707	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CDK1—thyroid cancer	4.32e-05	0.00651	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—SST—thyroid cancer	4.28e-05	0.00645	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PTCH1—thyroid cancer	4.25e-05	0.00641	CbGpPWpGaD
Rimonabant—CNR1—BDNF signaling pathway—HRAS—thyroid cancer	4.23e-05	0.00638	CbGpPWpGaD
Rimonabant—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	4.16e-05	0.00628	CbGpPWpGaD
Rimonabant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	4.14e-05	0.00625	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—CALCA—thyroid cancer	4.12e-05	0.00621	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TCF7L1—thyroid cancer	4.03e-05	0.00608	CbGpPWpGaD
Rimonabant—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	3.98e-05	0.00601	CbGpPWpGaD
Rimonabant—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	3.95e-05	0.00596	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—SST—thyroid cancer	3.89e-05	0.00586	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TSHR—thyroid cancer	3.76e-05	0.00567	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CALCA—thyroid cancer	3.74e-05	0.00564	CbGpPWpGaD
Rimonabant—CNR1—BDNF signaling pathway—AKT1—thyroid cancer	3.74e-05	0.00564	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PRKAR1A—thyroid cancer	3.7e-05	0.00558	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MEN1—thyroid cancer	3.54e-05	0.00533	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CDK1—thyroid cancer	3.39e-05	0.00511	CbGpPWpGaD
Rimonabant—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	3.38e-05	0.00509	CbGpPWpGaD
Rimonabant—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	3.21e-05	0.00485	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PTCH1—thyroid cancer	3.2e-05	0.00482	CbGpPWpGaD
Rimonabant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	3.2e-05	0.00482	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TSHR—thyroid cancer	2.95e-05	0.00445	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—SST—thyroid cancer	2.93e-05	0.00441	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PRKAR1A—thyroid cancer	2.9e-05	0.00438	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CALCA—thyroid cancer	2.82e-05	0.00425	CbGpPWpGaD
Rimonabant—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	2.8e-05	0.00422	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MEN1—thyroid cancer	2.78e-05	0.00419	CbGpPWpGaD
Rimonabant—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	2.61e-05	0.00393	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	2.56e-05	0.00386	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CDK1—thyroid cancer	2.55e-05	0.00384	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PTCH1—thyroid cancer	2.51e-05	0.00379	CbGpPWpGaD
Rimonabant—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	2.39e-05	0.00361	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—SST—thyroid cancer	2.3e-05	0.00346	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	2.23e-05	0.00336	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CALCA—thyroid cancer	2.21e-05	0.00333	CbGpPWpGaD
Rimonabant—CYP2D6—Biological oxidations—RXRA—thyroid cancer	2.12e-05	0.00319	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—RXRA—thyroid cancer	2.1e-05	0.00316	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—NRG1—thyroid cancer	2.05e-05	0.00309	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CDK1—thyroid cancer	2e-05	0.00302	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	1.99e-05	0.003	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	1.91e-05	0.00287	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TERT—thyroid cancer	1.84e-05	0.00277	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—RXRA—thyroid cancer	1.79e-05	0.0027	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—HIF1A—thyroid cancer	1.76e-05	0.00265	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	1.71e-05	0.00258	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—NRG1—thyroid cancer	1.61e-05	0.00242	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—MINPP1—thyroid cancer	1.56e-05	0.00235	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—NRAS—thyroid cancer	1.55e-05	0.00233	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—MINPP1—thyroid cancer	1.54e-05	0.00232	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	1.46e-05	0.0022	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—BRAF—thyroid cancer	1.46e-05	0.00219	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TERT—thyroid cancer	1.44e-05	0.00217	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—RXRA—thyroid cancer	1.38e-05	0.00209	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—HIF1A—thyroid cancer	1.38e-05	0.00208	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—KRAS—thyroid cancer	1.33e-05	0.00201	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—NDUFA13—thyroid cancer	1.32e-05	0.00199	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—MINPP1—thyroid cancer	1.32e-05	0.00199	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—NDUFA13—thyroid cancer	1.31e-05	0.00198	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CHST14—thyroid cancer	1.24e-05	0.00187	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CHST14—thyroid cancer	1.23e-05	0.00186	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—NRAS—thyroid cancer	1.21e-05	0.00183	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—BRAF—thyroid cancer	1.14e-05	0.00172	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—HRAS—thyroid cancer	1.13e-05	0.00171	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—NDUFA13—thyroid cancer	1.12e-05	0.00169	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—AKT1—thyroid cancer	1.1e-05	0.00166	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CCND1—thyroid cancer	1.06e-05	0.0016	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CHST14—thyroid cancer	1.05e-05	0.00159	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—KRAS—thyroid cancer	1.05e-05	0.00158	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PTEN—thyroid cancer	1.03e-05	0.00155	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.02e-05	0.00153	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—HPGD—thyroid cancer	1e-05	0.00151	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—AKT1—thyroid cancer	1e-05	0.00151	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—HPGD—thyroid cancer	9.93e-06	0.0015	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—NRAS—thyroid cancer	9.15e-06	0.00138	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—HRAS—thyroid cancer	8.89e-06	0.00134	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—NDUFA13—thyroid cancer	8.64e-06	0.0013	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—AKT1—thyroid cancer	8.64e-06	0.0013	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—HPGD—thyroid cancer	8.49e-06	0.00128	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CCND1—thyroid cancer	8.33e-06	0.00126	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CHST14—thyroid cancer	8.13e-06	0.00123	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.06e-06	0.00122	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PTEN—thyroid cancer	8.04e-06	0.00121	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—KRAS—thyroid cancer	7.87e-06	0.00119	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—AKT1—thyroid cancer	7.85e-06	0.00118	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—NRAS—thyroid cancer	7.18e-06	0.00108	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TP53—thyroid cancer	7e-06	0.00105	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.89e-06	0.00104	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—HRAS—thyroid cancer	6.69e-06	0.00101	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—HPGD—thyroid cancer	6.55e-06	0.000988	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—KRAS—thyroid cancer	6.18e-06	0.000931	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—AKT1—thyroid cancer	5.91e-06	0.000891	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—TPR—thyroid cancer	5.76e-06	0.000868	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—TPR—thyroid cancer	5.71e-06	0.00086	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	5.66e-06	0.000854	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	5.61e-06	0.000846	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TP53—thyroid cancer	5.49e-06	0.000828	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—HRAS—thyroid cancer	5.25e-06	0.000792	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.09e-06	0.000767	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—TPR—thyroid cancer	4.88e-06	0.000735	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	4.8e-06	0.000723	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—AKT1—thyroid cancer	4.64e-06	0.000699	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.35e-06	0.000656	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—SLC5A5—thyroid cancer	4.31e-06	0.00065	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—SLC5A5—thyroid cancer	4.27e-06	0.000644	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4e-06	0.000604	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—TPR—thyroid cancer	3.76e-06	0.000567	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.7e-06	0.000558	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—SLC5A5—thyroid cancer	3.65e-06	0.00055	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—RXRA—thyroid cancer	3.62e-06	0.000546	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—RXRA—thyroid cancer	3.59e-06	0.000541	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.49e-06	0.000526	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.42e-06	0.000516	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—RXRA—thyroid cancer	3.07e-06	0.000462	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.98e-06	0.00045	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.82e-06	0.000425	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—RXRA—thyroid cancer	2.37e-06	0.000357	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PPARG—thyroid cancer	2.29e-06	0.000345	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PPARG—thyroid cancer	2.27e-06	0.000342	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PPARG—thyroid cancer	1.94e-06	0.000292	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.8e-06	0.000271	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.78e-06	0.000269	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PTEN—thyroid cancer	1.57e-06	0.000236	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PTEN—thyroid cancer	1.55e-06	0.000234	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PTGS2—thyroid cancer	1.52e-06	0.00023	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PPARG—thyroid cancer	1.49e-06	0.000225	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PTEN—thyroid cancer	1.33e-06	0.0002	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.18e-06	0.000177	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PTEN—thyroid cancer	1.03e-06	0.000155	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—AKT1—thyroid cancer	9.04e-07	0.000136	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—AKT1—thyroid cancer	8.96e-07	0.000135	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—AKT1—thyroid cancer	7.66e-07	0.000115	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—AKT1—thyroid cancer	5.91e-07	8.91e-05	CbGpPWpGaD
